A randomized phase III trial evaluated the effect of adding lapatinib to paclitaxel as first-line therapy for patients with metastatic breast cancer whose tumors were negative or untested for human epidermal growth factor receptor 2 (HER2) overexpression. Progression-free survival was prolonged significantly in patients with HER2-overexpressing tumors, which indicates that lapatinib exerts its main effects via the HER2 pathway.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Dual targeting micelles loaded with paclitaxel and lapatinib for combinational therapy of brain metastases from breast cancer
Scientific Reports Open Access 16 February 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Parkin, D. M., Bray, F., Ferlay, J. & Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74–108 (2005).
Johnston, J. B. et al. Targeting the EGFR Pathway for Cancer Therapy. Curr. Medicinal Chem. 13, 3483–3492 (2006).
Jin, Q. & Esteva, F. J. Cross-talk between the ErbB/HER Family and the type I Insulin- like growth factor receptor signaling pathway in breast cancer. J. Mammary Gland Biol. Neoplasia 13, 485–498 (2008).
Gomez, H. L. et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J. Clin. Oncol. 26, 2999–3005 (2008).
Cameron, D. et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res. Treat. 10, 1007 (2008).
Herendeen, J. M. et al. An open label, fixed sequence, two period study to evaluate the potential induction of GW572016 metabolism by carbamazepine [Abstract]. ASCO Meeting Abstracts 22, 3081 (2004).
Beulz-Riche, D., Robert, J., Riché, C. & Ratanasavanh, D. Effects of paclitaxel, cyclophosphamide, ifosfamide, tamoxifen and cyclosporine on the metabolism of methoxymorpholinodoxorubicin in human liver microsomes. Cancer Chemother. Pharmacol. 49, 274–280 (2002).
Jones, S. F. et al. A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009) [Abstract]. ASCO Meeting Abstracts 22, 2083 (2004).
Cristofanilli, M. et al. A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC) [Abstract]. San Antonio Breast Cancer Symposium, 2006 December 14–17, San Antonio, TX.
Di Leo, A. et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J. Clin. Oncol. 26, 5544–5552 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Castañeda, C., Gomez, H. Combined lapatinib and paclitaxel in HER2-positive breast cancer. Nat Rev Clin Oncol 6, 308–309 (2009). https://doi.org/10.1038/nrclinonc.2009.68
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2009.68
This article is cited by
-
Dual targeting micelles loaded with paclitaxel and lapatinib for combinational therapy of brain metastases from breast cancer
Scientific Reports (2022)
-
Wound repair: role of immune–epithelial interactions
Mucosal Immunology (2015)